Blood test strategy could guide better lung cancer treatment
NCT ID NCT02856893
Summary
This study is testing the best way to use the drug osimertinib for advanced lung cancer with a specific genetic change (EGFR mutation). It compares starting osimertinib right away versus starting another drug first and switching to osimertinib later, guided by a blood test that looks for cancer DNA. The main goal is to see which approach keeps the cancer from growing for the longest time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Assistance Publique - Hopitaux de Marseille - Hopital Nord
Marseille, France
-
CHU Toulouse - Hopital Larrey
Toulouse, France
-
CHU de Brest
Brest, France
-
Centre Francois Baclesse
Caen, France
-
Centre Hopitalier Intercommunal De Creteil
Créteil, France
-
Centre Paul Strauss
Strasbourg, France
-
Gustave Roussy
Villejuif, France
-
Hospital Clinic Universitari de Barcelona
Barcelona, Spain
-
Hospital De La Santa Creu I Sant Pau
Barcelona, Spain
-
Hospital Universitario 12 De Octubre
Madrid, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, Spain
-
Institut Bergonie
Bordeaux, France
-
Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro
Mataró, Spain
-
Institut Jules Bordet
Brussels, Bruxelles Région, 1070, Belgium
-
Institut Paoli-Calmettes
Marseille, France
-
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France
-
King Hussein Cancer Center
Amman, Jordan
-
Medical University of Gdansk
Gdansk, Poland
-
The Institute Of Oncology
Ljubljana, Slovenia
-
University Clinic Golnik
Golnik, Slovenia
-
University Hospital A Coruna-Hospital Teresa Herrera
A Coruña, Spain
-
Vall d'Hebron Institut d'Oncologia
Barcelona, Spain
-
Virgen del Rocio University Hospital
Seville, Spain
Conditions
Explore the condition pages connected to this study.